A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMML.
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2018
At a glance
- Drugs Azacitidine (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 28 Jul 2018 Planned number of patients changed from 65 to 24.
- 28 Jul 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2021.
- 06 Aug 2017 Planned End Date changed from 1 Jan 2016 to 1 Jan 2018.